Clinical Trials Archive

A building with a stone facade displays a sign that reads
The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry)
A building with a stone facade displays a sign that reads
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
A building with a stone facade displays a sign that reads
ELEVATE High-Risk PCI Pivotal Study
A building with a stone facade displays a sign that reads
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
A building with a stone facade displays a sign that reads
HUD Enterra Therapy Gastric Electrical Stimulation System
A building with a stone facade displays a sign that reads
The RAPID – PE Study: RESCUE Advanced Protocol Without ICU Stay and no Lytic Drip – for the Treatment of Pulmonary Embolism
A building with a stone facade displays a sign that reads
A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients with Metastatic Colorectal Carcinoma
A building with a stone facade displays a sign that reads
A Pilot Human Investigation of the Safety, Tolerability and Effectiveness of the Aqua Medical Circumferential RF Vapor (RFV) Ablation System for Duodenal Mucosal Ablation for the Management of Type-2 Diabetes Mellitus (STEAM T-2DM Pilot)
A building with a stone facade displays a sign that reads
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)